SYSTEMATIC LITERATURE REVIEW FOR TREATMENT OUTCOMES (INCLUDING IMMUNO-ONCOLOGY TREATMENT) AMONG PATIENTS WITH STAGE 3 UNRESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：1
|
作者：
Zhou, Z. [1 ]
Song, J. [2 ]
Ouwens, M. J. [3 ]
Huhn, M. [3 ]
Jiang, H. [4 ]
Zhang, Y. [4 ]
Dalevi, D. [3 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Anal Grp Inc, Los Angeles, CA USA
[3] Astrazeneca, Molndal, Sweden
[4] Astrazeneca, Gaithersburg, MD USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.110
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN28
引用
收藏
页码：A416 / A416
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer
    Yeh, Justin
    Marrone, Kristen A.
    Forde, Patrick M.
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S451 - S459
  • [2] The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
    Low, Jia Li
    Walsh, Robert J.
    Ang, Yvonne
    Chan, Gloria
    Soo, Ross A.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [3] Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)
    Priyanka Patel
    Doraid Alrifai
    Fiona McDonald
    Martin Forster
    [J]. British Journal of Cancer, 2020, 123 : 18 - 27
  • [4] Atezolizumab in non-small cell lung cancer: the era of precision immuno-oncology
    Chow, James Chung Hang
    Cheung, Ka Man
    Cho, William Chi Shing
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (12)
  • [5] Real-world treatment patterns and outcomes among unresectable Stage III Non-Small Cell Lung Cancer
    Arunachalam, Ashwini
    Sura, Sneha
    Murphy, John
    Conkling, Paul
    Goldschmidt, Jerome
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E13 - E13
  • [6] Association of retinoblastoma function with response to immuno-oncology treatment in patients with small cell lung cancer
    Balli, David
    Wang, Xuya
    Rizvi, Naiyer A.
    Chan, Timothy A.
    Dowlati, Afshin
    Doshi, Parul
    Chang, Han
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [7] Optimal Treatment of Unresectable Stage III Non-Small Cell Lung Cancer
    Bradley, Jeffrey D.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 853 - 855
  • [8] Real World Treatment Patterns and Outcomes among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy
    Arunachalam, A.
    Vasudevan, A.
    Sura, S.
    Murphy, J.
    Goldschmidt, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S264 - S265
  • [9] Dual immuno-oncology agents as neoadjuvant therapy for patients with resectable non-small cell lung cancer
    Adachi, Hiroyuki
    Ito, Hiroyuki
    Nagashima, Takuya
    Isaka, Tetsuya
    Saito, Aya
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (02) : 229 - 235
  • [10] Impact of Lymphopenia on Treatment Outcomes in Unresectable Non-Small Cell Lung Cancer
    Amorelli, F.
    Martinez, A.
    Liu, F.
    Foro, P.
    Algara, M.
    Sanz, J.
    Membrive, I.
    Taus, A.
    Arriola, E.
    Masfarre, L.
    Navarro, N.
    Rodriguez De Dios, N.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E2 - E3
12345